✦ LIBER ✦

T1234 Active Therapeutic Immunization Against TNF With a TNF-Kinoid in Crohn's Disease Patients: A Phase 1-2 Study

✍ Scribed by Rogler, Gerhard; Michetti, Pierre F.; Kruger, Frederik C.; van der Bijl, Anina; Kruger, Dawid S.; Malan, François; Grouard-Vogel, Geraldine; Dhellin, Olivier; Fanget, Bernard; Vandepapeliere, Pierre

Book ID: 122846472
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 48 KB
Volume: 138
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(10)62389-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Su2091 Results of a Phase II, Randomized

Su2091 Results of a Phase II, Randomized, Double Blind, Controlled Trial of the Efficacy of Active Therapeutic Immunization With TNF-Kinoid in Patients With Moderate to Severe Crohn's Disease With Secondary Resistance to TNFα Antagonist

✍ Dewit, Olivier; Hebuterne, Xavier; Dupas, Jean-Louis; Howaldt, Stefanie M.; Bure 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 176 KB

Intravenous CDP870, a humanized anti-TNF

Intravenous CDP870, a humanized anti-TNF antibody fragment, in patients with active Crohn's disease—An exploratory study

✍ Winter, Trevor; Wright, John; Ghosh, Subrata; Jahnsen, Joergen; Patel, Jatin 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 169 KB

Sargramostim in patients with Crohn’s di

Sargramostim in patients with Crohn’s disease: results of a phase 1–2 study

✍ Masakazu Takazoe; Toshiyuki Matsui; Satoshi Motoya; Takayuki Matsumoto; Toshifum 📂 Article 📅 2009 🏛 Springer Japan 🌐 English ⚖ 227 KB

A phase 1/2A Trial of STA 5326, an oral

A phase 1/2A Trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease

✍ Robert Burakoff; Charles F. Barish; Dennis Riff; Ronald Pruitt; William Y. Chey; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 258 KB

P300 Health related quality of life resu

✍ B. Feagan; C. Gasink; L.-L. Gao; M. Blank; J. Johanns; C. Guzzo; C.-F. Chiou; W. 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 67 KB

A Multicenter, Randomized, Double-Blind,

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase2b Study of Ustekinumab, a Human Monoclonal Antibody to IL-12/23p40, in Patients With Moderately to Severely Active Crohn's Disease: Results Through Week 22 From the Certifi Trial

✍ William J. Sandborn; Christopher Gasink; Long-Long Gao; Marion Blank; Jewel Joha 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 145 KB